Quantcast
Last updated on April 16, 2014 at 8:05 EDT

Latest Tenofovir Stories

2009-08-03 09:52:28

A member of a new class of antiretroviral drugs is safe and effective for patients beginning treatment against HIV, according to researchers who have completed a two-year multisite phase III clinical trial comparing it with standard antiretroviral drugs.The results are online and scheduled for publication in an upcoming issue of the Lancet.Lead author of the Lancet article is Jeffrey Lennox, MD, professor of medicine (infectious diseases) at Emory University School of Medicine. Lennox is...

2009-07-20 07:00:00

CAPE TOWN, South Africa, July 20 /PRNewswire/ -- New data became available today at the 5(th) International AIDS Society Conference from ARTEN (Atazanavir/Ritonavir on a background of Tenofovir and Emtricitabine [Truvada(R)] versus Nevirapine). ARTEN is an open-label, multi-center and international non-inferiority clinical trial. It is the first large study to directly compare the efficacy and safety of nevirapine and ritonavir-boosted atazanavir (ATV/r) when combined with TDF/FTC, a...

2009-07-16 15:28:00

CORK, Ireland, July 16 /PRNewswire/ --Tibotec Pharmaceuticals today announced that it has entered into a license and collaboration agreement with Gilead Sciences, Inc. for the development and commercialization of a new once-daily fixed-dose antiretroviral product containing Tibotec's investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride 25 mg) and Gilead's Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) for...

2009-07-15 07:30:00

KENILWORTH, N.J., July 15 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that it has extended to stage two an ongoing Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. In this study, vicriviroc is being evaluated in a novel nucleoside-sparing regimen that is designed to provide additional options for treatment-naive patients...

2009-03-30 15:34:00

PITTSBURGH, March 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.2% controlling interest, has received the first tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg. Mylan Vice Chairman...

2009-02-10 23:52:16

AIDS researchers meeting in Montreal say anitretroviral drugs given by vaginal gel may be effective at preventing HIV infection. The Washington Post reported Tuesday that two experiments in monkeys showed oral or vaginal treatment of tenofovir, or a combination drug that also contained emtricitabine, was highly effective in blocking HIV infection. A third study, which involved 3,100 women in the United States and Africa, found a microbicide vaginal gel called PRO 2000/5 prevented HIV from...

2008-11-03 09:00:40

Gilead Sciences, a biopharmaceutical company, has presented two-year data from two Phase III pivotal clinical trials, studies 102 and 103, evaluating the safety and efficacy of once-daily Viread among adult patients with chronic hepatitis B virus infection. These new data show that patients who received Viread for up to 96 weeks experienced sustained suppression of hepatitis B virus (HBV) levels in the blood (91% and 78% for Studies 102 and 103, respectively). The studies also show that all...

2008-11-01 12:00:15

Gilead Sciences, Inc. (Nasdaq:GILD) today announced the presentation of two-year (96-week) data from two Phase III pivotal clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread(R) (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection. These data will be presented during oral sessions at the annual meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2008) being held this...

2008-10-26 12:00:10

In a new Phase III study that compared Merck & Co., Inc.'s HIV integrase inhibitor ISENTRESS(R) (raltegravir) to efavirenz (one of the leading antiretrovirals prescribed for previously untreated (treatment-naive) HIV-infected patients), ISENTRESS reduced HIV viral load to undetectable levels (less than 50 copies/mL) in 86 percent of patients compared to 82 percent of patients treated with efavirenz in previously untreated HIV patients at Week 48. Both medicines were taken in combination...

2008-08-14 03:00:47

Gilead Sciences has announced that the FDA has granted marketing approval for Viread for the treatment of chronic hepatitis B, a liver disease caused by the hepatitis B virus. Viread is now also indicated for the treatment of chronic hepatitis B in adults. The drug is administered as a once-daily tablet, and works by blocking hepatitis B virus DNA polymerase, the enzyme that is necessary for the virus to replicate in liver cells. Viread has been available in the US as a treatment for HIV...